Truist analyst Asthika Goonewardene lowered the firm’s price target on Mersana Therapeutics (MRSN) to $36 from $250 and keeps a Buy rating on the shares after having updated the firm’s model to account for the company’s 1-for-25 reverse stock split and Q2 update. The firm remains optimistic that with new side-effect management protocols, Emi-Le can get better exposure and responses at the higher dose, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSN:
- Mersana Therapeutics Faces Financial Strain Amid U.S. Tariff Uncertainties
- Mersana Therapeutics Reports Q2 2025 Financial Results
- Mersana Therapeutics price target adjusted to $17 at BTIG after reverse split
- Promising Progress and Strategic Focus Drive Buy Rating for Mersana Therapeutics
- Mersana Therapeutics reports Q2 EPS ($4.87), consensus ($4.25)